Risultati per: Screening del cancro alla prostata

Secondo l’Oms, questa neoplasia miete ogni anno più vittime dei tumori al colon, al seno e al fegato messi insieme

This randomized clinical trial examines whether patient navigation improves lung cancer screening completion among people experiencing homelessness.

The National Lung Screening Trial, a landmark randomized clinical trial that demonstrated the efficacy of lung cancer screening with low-dose computed tomography (LDCT), was published more than a decade ago. In the interim, the US Preventive Services Task Force has endorsed lung cancer screening in certain adults, insurance coverage of LDCT has expanded, and a second large randomized clinical trial, the NELSON trial, demonstrated that LDCT can reduce lung cancer mortality. Importantly, annual LDCT screening also carries risks. In a recent observational study, approximately 32% of those screened underwent additional imaging, 3% had invasive testing, and 31% of those who received invasive testing had a complication.

This cross-sectional study investigates the prevalence of up-to-date lung cancer screening across the 50 US states and the District of Columbia in 2022.

This cohort study estimates the effectiveness, acceptability, and feasibility of dispensing mifepristone for medication abortion using a mail-order pharmacy.

New England Journal of Medicine, Volume 391, Issue 5, Page 468-474, August 1, 2024.

Scopo del progetto, del valore di 10 milioni di euro di cui 3,8 finanziati da Regione Lombardia, è l’aggiornamento tecnologico del sincrotrone per produrre elio, ossigeno e litio

Celiac disease (CD) is a common yet underdiagnosed autoimmune disease with substantial long-term consequences. High-accuracy point-of-care tests (POCTs) for CD antibodies conducted at youth primary healthcare centers (YHCCs) may enable earlier identification of CD, but evidence about the cost-effectiveness of such strategies is lacking. We estimated the long-term cost-effectiveness of active case-finding and mass-screening compared to clinical detection in the Netherlands.

Objective
We assessed the availability and readiness of health facilities to provide cervical cancer screening services in Nepal.

Design
Cross-sectional study.

Setting
We used secondary data from a nationally representative 2021 Nepal Health Facility Survey, specifically focusing on the facilities offering cervical cancer screening services.

Outcome measures
We defined the readiness of health facilities to provide cervical cancer screening services using the standard WHO service availability and readiness assessment manual.

Results
The overall readiness score was 59.1% (95% CI 55.4% to 62.8%), with more equipment and diagnostic tests available than staff and guidelines. Public hospitals (67.4%, 95% CI 63.0% to 71.7%) had the highest readiness levels. Compared with urban areas, health facilities in rural areas had lower readiness. The Sudurpashchim, Bagmati and Gandaki provinces had higher readiness levels (69.1%, 95% CI 57.7% to 80.5%; 60.1%, 95% CI 53.4% to 66.8%; and 62.5%, 95% CI 56.5% to 68.5%, respectively). Around 17% of facilities had trained providers and specific guidelines to follow while providing cervical cancer screening services. The basic healthcare centres (BHCCs) had lower readiness than private hospitals. Facility types, province and staff management meetings had heterogeneous associations with three conditional quantile scores.

Conclusion
The availability of cervical cancer screening services is limited in Nepal, necessitating urgent action to expand coverage. Our findings suggest that efforts should focus on improving the readiness of existing facilities by providing training to healthcare workers and increasing access to guidelines. BHCCs and healthcare facilities in rural areas and Karnali province should be given priority to enhance their readiness.

Le forme più gravi aumentano ancora di più il pericolo

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Analizzati 1.923 campioni di 250 pazienti

Introduction
Lung cancer is the most common cause of cancer death globally. In 2022 the UK National Screening Committee recommended the implementation of a national targeted lung cancer screening programme, aiming to improve early diagnosis and survival rates. Research studies and services internationally consistently observe socioeconomic and smoking-related inequalities in screening uptake. Pathway navigation (PN) is a process through which a trained pathway navigator guides people to overcome barriers to accessing healthcare services, including screening. This nested randomised controlled trial aims to determine whether a PN intervention results in more individuals participating in lung cancer screening compared with the usual written invitation within a previous non-responder population as part of the Yorkshire Lung Screening Trial (YLST).

Methods and analysis
A two-arm randomised controlled trial and process evaluation nested within the YLST. Participants aged 55–80 (inclusive) who have not responded to previous postal invitations to screening will be randomised by household to receive PN or usual care (a further postal invitation to contact the screening service for a lung health check) between March 2023 and October 2024. The PN intervention includes a postal appointment notification and prearranged telephone appointment, during which a pathway navigator telephones the participant, following a four-step protocol to introduce the offer and conduct an initial risk assessment. If eligible, participants are invited to book a low-dose CT (LDCT) lung cancer screening scan. All pathway navigators receive training from behavioural psychologists on motivational interviewing and communication techniques to elicit barriers to screening attendance and offer solutions.

Coprimary outcomes
The number undergoing initial telephone assessment of lung cancer risk. The number undergoing an LDCT screening scan.
Secondary outcomes include demographic, clinical and risk parameters of people undergoing telephone risk assessment; the number of people eligible for screening following telephone risk assessment; the number of screen-detected cancers diagnosed; costs and a mixed-methods process evaluation.
Descriptive analyses will be used to present numbers, proportions and quantitative components of the process evaluation. Primary comparisons of differences between groups will be made using logistic regression. Applied thematic analysis will be used to interpret qualitative data within a conceptual framework based on the COM-B framework. A health economic analysis of the PN intervention will also be conducted.

Ethics and dissemination
The study is approved by the Greater Manchester West Research Ethics Committee (18-NW-0012) and the Health Research Authority following the Confidentiality Advisory Group review. Results will be shared through peer-reviewed scientific journals, conference presentations and on the YLST website.

Trial registration numbers
ISRCTN42704678 and NCT03750110.